Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.76 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923892 | 0.94 | NTRK1 (0.74) | NTRK1NTRK2MAPK1TP53PDGFRB | |
| SCHEMBL1923890 | 0.93 | NTRK1 (0.73) | NTRK1NTRK2MAPK1TP53PDGFRB | |
| SCHEMBL3980180 | 0.87 | NTRK1 (0.80) | NTRK1NTRK2MAPK1PDGFRBFPR2 | |
| SCHEMBL1924757 | 0.87 | NTRK1 (1.00) | NTRK1NTRK2MAPK1PDGFRB | |
| SCHEMBL1924946 | 0.86 | NTRK1 (0.75) | NTRK1NTRK2MAPK1PDGFRBFPR2 | |
| SCHEMBL1925521 | 0.85 | NTRK1 (0.83) | NTRK1NTRK2MAPK1PDGFRBALDH1A1 | |
| SCHEMBL1923992 | 0.85 | NTRK1 (0.83) | NTRK1NTRK2MAPK1PDGFRBALDH1A1 | |
| SCHEMBL1925441 | 0.85 | NTRK1 (0.83) | NTRK1NTRK2MAPK1PDGFRBALDH1A1 | |
| SCHEMBL1924486 | 0.84 | NTRK1 (0.91) | NTRK1NTRK2MAPK1PDGFRB | |
| SCHEMBL1924937 | 0.84 | NTRK1 (0.88) | NTRK1NTRK2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | NTRK1 3/4885NTRK2 1/4885MAPK1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.